Review of pneumococcal conjugate vaccine in adults: implications on clinical development

被引:31
|
作者
Abraham-Van Parijs, B
机构
[1] GlaxoSmithKline, Clin Dev & Med Affairs N America, Antiinfect, Collegeville, PA 19460 USA
[2] Wyeth Pharmaceut, Global Med Affairs Vaccines, Collegeville, PA 19426 USA
关键词
pneumococcal; conjugate vaccine; adults;
D O I
10.1016/j.vaccine.2004.01.029
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
A literature review was conducted to determine if pneumococcal conjugate vaccines administered to healthy and immunocompromised adults, in comparison with the known efficacy in children, showed immunogenicity. Fifteen publications were retrieved. Clinical studies had been conducted using vaccines from different manufacturers, in different populations, using varied methodologies. No clear evidence of the superiority of the conjugate vaccine over the currently licensed polysaccharide vaccine emerged. Possible reasons for the lack of superiority and its implications on vaccine development are discussed. (C) 2003 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1362 / 1371
页数:10
相关论文
共 50 条
  • [41] Pneumococcal conjugate vaccine in adults: Let's see what happens
    Paradiso, Peter R.
    [J]. HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2016, 12 (07) : 1906 - 1907
  • [42] Pneumococcal 13-valent conjugate vaccine for the prevention of invasive pneumococcal disease in children and adults
    Gladstone, Rebecca A.
    Jefferies, Johanna M.
    Faust, Saul N.
    Clarke, Stuart C.
    [J]. EXPERT REVIEW OF VACCINES, 2012, 11 (08) : 889 - 902
  • [43] Development of pneumococcal polysaccharide conjugate vaccine with long spacer arm
    Wu, Dinglong
    Ji, Shaoyang
    Hu, Tao
    [J]. VACCINE, 2013, 31 (48) : 5623 - 5626
  • [44] Spatial Variability in the Persistence of Pneumococcal Conjugate Vaccine-targeted Pneumococcal Serotypes Among Adults
    Warren, Joshua L.
    Pingali, S. Cassandra
    Weinberger, Daniel M.
    [J]. EPIDEMIOLOGY, 2017, 28 (01) : 119 - 126
  • [45] A Review of the Impact of Pneumococcal Polysaccharide Conjugate Vaccine (7-valent) on Pneumococcal Meningitis
    Htar, Myint Tin Tin
    Madhava, Harish
    Balmer, Paul
    Christopoulou, Dina
    Menegas, Damianos
    Bonnet, Eric
    [J]. ADVANCES IN THERAPY, 2013, 30 (08) : 748 - 762
  • [46] A Review of the Impact of Pneumococcal Polysaccharide Conjugate Vaccine (7-valent) on Pneumococcal Meningitis
    Myint Tin Tin Htar
    Harish Madhava
    Paul Balmer
    Dina Christopoulou
    Damianos Menegas
    Eric Bonnet
    [J]. Advances in Therapy, 2013, 30 : 748 - 762
  • [47] Health and economic outcomes of 20-valent pneumococcal conjugate vaccine compared to 15-valent pneumococcal conjugate vaccine strategies for adults in Greece
    Gourzoulidis, George
    Barmpouni, Myrto
    Kossyvaki, Vasiliki
    Vietri, Jeffrey
    Tzanetakos, Charalampos
    [J]. FRONTIERS IN PUBLIC HEALTH, 2023, 11
  • [49] Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults
    Jackson, Lisa A.
    Gurtman, Alejandra
    van Cleeff, Martin
    Jansen, Kathrin U.
    Jayawardene, Deepthi
    Devlin, Carmel
    Scott, Daniel A.
    Emini, Emilio A.
    Gruber, William C.
    Schmoele-Thoma, Beate
    [J]. VACCINE, 2013, 31 (35) : 3577 - 3584
  • [50] Impact of the pediatric 13-valent pneumococcal conjugate vaccine on serotype distribution and clinical characteristics of pneumococcal pneumonia in adults: The Japan Pneumococcal Vaccine Effectiveness Study (J-PAVE)
    Sando, Eiichiro
    Suzuki, Motoi
    Furumoto, Akitsugu
    Asoh, Norichika
    Yaegashi, Makito
    Aoshima, Masahiro
    Ishida, Masayuki
    Hamaguchi, Sugihiro
    Otsuka, Yoshihito
    Morimoto, Konosuke
    [J]. VACCINE, 2019, 37 (20) : 2687 - 2693